ENTBF - Entheon inks DMT drug supply agreement with Ofichem
Entheon Biomedical (ENTBF) has entered into a drug-supply agreement with Laboratorium Ofichem BV.Under the terms of the agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine drug substances ("DMT").Ofichem will provide GMP DMT product as well as the required analytical data package for use in the previously announced phase 1 human trial.The phase 1 trial, to be conducted in the Netherlands, is scheduled to begin in Q4 2021.
For further details see:
Entheon inks DMT drug supply agreement with Ofichem